AXCYNSIS AXCYNSIS THERAPEUTICS
LIVE

Serial Number

79407408

Owner

AXCYNSIS THERAPEUTICS PTE. LTD.

Attorney

Joseph G. Chu

Filing Date

Jul 23, 2024

Add to watchlist:

No watchlists yet
View on USPTO

AXCYNSIS AXCYNSIS THERAPEUTICS Trademark

Serial Number: 79407408 • Registration: 7989011

AXCYNSIS AXCYNSIS THERAPEUTICS is a trademark filed by AXCYNSIS THERAPEUTICS PTE. LTD. on July 23, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

AXCYNSIS THERAPEUTICS PTE. LTD.

41 SCIENCE PARK ROAD,

Entity Type: 24

Trademark Details

Filing Date

July 23, 2024

Registration Date

October 21, 2025

Published for Opposition

September 2, 2025

Goods & Services

Medical testing services in the nature of in vitro testing for medical diagnostic and treatment purposes and in vitro testing of pharmaceuticals; medical analysis services in the nature of in vitro analysis for medical diagnostic and treatment purposes and in vitro analysis in the nature of testing, inspection, or research of pharmaceuticals.

Development of pharmaceuticals; pharmaceutical research and development; research and development for the pharmaceutical industry; biochemical research; biochemical research and analysis; biochemical research and development; biochemistry research services; bioinorganic chemistry research; biological research; biological research and analysis; biological research laboratory services; biological research services; biomedical research services; bioorganic chemistry research; biotechnological research; biotechnology research; chemical research; chemical research and analysis; chemical research and analysis services; chemical research laboratory services; chemical research services; technological research in the field of chemistry; chemistry research; clinical research in the field of antibody drug conjugates in oncology; consultancy in the field of pharmaceutical research; consultancy in the field of scientific research; consultancy in the field of technological research relating to pharmaceutical studies; consultancy relating to pharmaceutical research and development; consultancy relating to pharmaceutical research and development in the field of therapeutics; DNA analysis services for scientific research purposes; DNA screening for scientific research purposes; DNA sequencing being DNA analysis for medical research purposes; DNA sequencing technology research; gene therapy research; scientific research in the field of genetics and antibody drug conjugates; genetic testing for scientific research purposes; laboratory research in the fields of antibody drug conjugates in oncology and antibody drug conjugate development; laboratory research in the field of chemistry; laboratory research in the field of gene expression; laboratory research in the field of pharmaceuticals; laboratory research services relating to pharmaceuticals; medical research; medical research in the field of oncology; medical research laboratory services; medical research services; pharmaceutical research and development services; pharmaceutical research consultancy; pharmaceutical research services; chemical research services in the nature of preparation of scientific reports relating to chemical research; scientific research services in the nature of preparation of scientific reports relating to scientific research; product research; product research and development; providing information about medical and scientific research in the field of pharmaceuticals; providing information relating to scientific research in the fields of biochemistry and biotechnology; providing information and online information about scientific and technological services in the field of antibody drug conjugates in oncology and research and design relating thereto; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; provision of information relating to scientific research; provision of information relating to technological research in the field of antibody drug conjugates in oncology; research services, namely, scientific research; research and development in the field of biotechnology; research and development of new products; research and development of new products for others; research and development services for the pharmaceutical industry; research and development services in the field of antibodies; research and development services in the field of antibody technology; research and development services in the field of biochemistry; research and development services in the field of biotechnology; research and development services in the field of chemistry; research and development services in the field of pharmaceutical preparations; research in the field of biology; research in the field of biomedicine; research in the field of biotechnology; research in the field of chemistry; research on the subject of pharmaceuticals; research relating to biotechnology; research relating to chemistry; research relating to chemicals; research relating to medicine in the nature of medical research; research relating to molecular sciences; research relating to pharmaceuticals; research relating to science; research laboratory analysis services in the field of chemistry and bioconjugation; research to develop new products; scientific and industrial research in the field of antibody drug conjugates in oncology; scientific and technological services, namely, research and design in the field of antibody drug conjugates in oncology; scientific and technological services, namely, research and development in the field of antibody drug conjugates in oncology; scientific research; scientific research and analysis for scientific research purposes; scientific research and development; scientific research for medical purposes; scientific research for medical purposes in the area of cancerous diseases; scientific research in the field of biotechnology; scientific research into the development of new products; scientific research relating to biology; scientific research relating to chemistry; scientific research relating to chemical products; scientific research relating to genetics; scientific research services; technical research in the field of pharmaceutical studies; technical research projects and studies in the field of antibody drug conjugates in oncology.

Pharmaceutical preparations for use in oncology; pharmaceutical drugs being pharmaceutical preparations for use in the treatment of cancer; pharmaceutical products, namely, pharmaceutical preparations for suppressing tumors; biopharmaceutical preparations for the treatment of cancer; chemical preparations for pharmaceutical purposes, namely, for oncology.

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
May 21, 2026 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Apr 30, 2026 FICS
FINAL DISPOSITION PROCESSED
Apr 30, 2026 FIMP
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Apr 9, 2026 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 23, 2026 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Mar 23, 2026 OPNR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 21, 2026 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Oct 21, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Oct 21, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 2, 2025 NPUB
PUBLISHED FOR OPPOSITION
Sep 2, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 27, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 29, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 28, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 28, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 28, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 28, 2025 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 25, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 24, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 24, 2025 TROA
REFUSAL PROCESSED BY IB
Mar 22, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 4, 2025 RFCS
REFUSAL PROCESSED BY MPU
Mar 4, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 16, 2025 RFCR
NON-FINAL ACTION WRITTEN
Jan 15, 2025 CNRT
ASSIGNED TO EXAMINER
Jan 10, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Nov 8, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 8, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 24, 2024 REPR